Does EmblemHealth Cover Metformin?

How EmblemHealth Classifies Metformin on Its Formulary

EmblemHealth uses a multi-tier formulary system, and generic metformin hydrochloride (both immediate-release and extended-release tablets) lands on Tier 1 across the insurer's commercial HMO, PPO, and EPO product lines. Tier 1 carries the lowest member cost-sharing of any drug tier.

EmblemHealth publishes its formulary lists annually with mid-year updates. On the 2025 and 2026 commercial formularies, metformin 500 mg, 850 mg, and 1,000 mg immediate-release tablets and metformin ER 500 mg and 750 mg tablets all appear at Tier 1 without prior authorization, step therapy, or quantity limits for standard dosing. This placement aligns with how nearly every major U.S. insurer handles metformin: a 2023 analysis in the Journal of Managed Care & Specialty Pharmacy found that 98.4% of commercial formularies listed metformin as a Tier 1 preferred generic.

The reason is straightforward. Metformin is the most prescribed diabetes medication in the United States, with over 90 million dispensed prescriptions annually according to IQVIA data reported by the FDA. Its wholesale acquisition cost for a 30-day supply of 2,000 mg daily falls below $4 at many retail pharmacies. Insurers have no financial incentive to restrict access to a drug this inexpensive and this well-supported by clinical evidence.

Brand-name metformin products tell a different story. Glucophage (brand immediate-release) and Glucophage XR (brand extended-release) sit on Tier 2 or Tier 3 on EmblemHealth formularies, and Glumetza (a branded extended-release formulation) often requires prior authorization. Members who want a brand-name version when a generic equivalent exists will pay the Tier 2/3 copay or coinsurance, which can range from $30 to $75 per fill depending on the specific plan.

What You Will Actually Pay Out of Pocket

For most EmblemHealth members, a 30-day supply of generic metformin costs between $0 and $15 at an in-network pharmacy. The exact amount depends on which EmblemHealth product you carry.

EmblemHealth GHI HMO and HIP HMO plans typically charge a flat $5 to $10 copay for Tier 1 generics. EmblemHealth's Essential Plan offerings (available to qualifying New York residents with household incomes up to 200% of the federal poverty level) charge $0 for preferred generics, making metformin entirely free at the point of sale. On EmblemHealth Medicare Advantage HMO plans, metformin is covered under Part D, and many of these plans advertise a $0 preferred generic copay during the initial coverage phase, consistent with trends reported in the Kaiser Family Foundation's 2024 Medicare Part D analysis.

Members with EmblemHealth PPO or EPO plans that use coinsurance instead of flat copays may pay 10% to 20% of the negotiated drug price. Even at 20% coinsurance, a drug with a negotiated price under $15 means the member's share stays under $3 per fill.

Mail-order pharmacy is another way to cut costs. EmblemHealth partners with CVS Caremark and Express Scripts (depending on the plan year and product) for mail-order fulfillment. Ordering a 90-day supply by mail typically costs the equivalent of two copays rather than three, saving roughly 33% over quarterly refills at a retail counter. For a drug as inexpensive as metformin, the absolute savings are modest ($5 to $10 per quarter), but they compound for members managing multiple chronic medications.

The American Diabetes Association's 2024 Standards of Care emphasizes that cost and access should factor into prescribing decisions. Metformin scores well on both counts under EmblemHealth plans.

Prior Authorization and Step Therapy: When They Apply

Generic metformin does not require prior authorization on any current EmblemHealth formulary. This is the norm across the insurance industry for a drug with decades of safety data and first-line guideline status.

Prior authorization enters the picture when a prescriber requests a non-preferred metformin formulation. Glumetza, the branded osmotic-delivery extended-release tablet, requires prior authorization on most EmblemHealth commercial plans. The insurer's clinical criteria typically demand documentation that the member tried and either failed or could not tolerate generic metformin ER before Glumetza is approved. This step-therapy requirement reflects the fact that Glumetza's average wholesale price exceeds $900 per month, compared to under $15 for generic metformin ER, while clinical outcomes data show no superiority of the brand over the generic for glycemic control.

A 2020 Cochrane review comparing immediate-release and extended-release metformin formulations found similar HbA1c reductions (mean difference 0.1%, not statistically significant) with modestly lower gastrointestinal side effects in the ER group. That evidence supports using generic ER tablets for patients who experience GI intolerance on immediate-release metformin, and EmblemHealth covers the generic ER switch without prior authorization.

Combination products that include metformin paired with another active ingredient (such as metformin/sitagliptin, marketed as Janumet) follow their own formulary placement rules. These are generally on Tier 2 or Tier 3 and may carry their own prior authorization or step-therapy requirements tied to the non-metformin component.

EmblemHealth Medicare Advantage and Metformin

EmblemHealth offers several Medicare Advantage plans in the New York metropolitan area, including the EmblemHealth VIP HMO and EmblemHealth Dual Assurance (D-SNP) plans. Metformin coverage under these plans falls under the Part D prescription drug benefit.

On the 2026 EmblemHealth VIP HMO formulary, metformin immediate-release and extended-release tablets are Tier 1 preferred generics with a $0 copay at preferred pharmacies during the initial coverage phase. This $0 copay is part of a broader trend: the Inflation Reduction Act of 2022 capped insulin costs at $35 per month for Medicare beneficiaries starting in 2023, and many Medicare Advantage insurers extended similar $0 generic drug incentives for first-line diabetes medications to remain competitive.

Once a Medicare Advantage member enters the coverage gap (the "donut hole"), the Inflation Reduction Act's provisions ensure that manufacturer discounts and plan contributions cover 75% of drug costs. For a drug as inexpensive as metformin, members in the coverage gap still pay very little out of pocket. The CMS 2025 Part D benefit parameters confirm that the initial coverage limit is $5,030 in total drug costs, and the catastrophic threshold is $8,000 in true out-of-pocket spending, though metformin alone is unlikely to push any member near these thresholds.

For EmblemHealth dual-eligible (Medicare-Medicaid) members, metformin copays are typically $0 to $1.55 for generics, consistent with the low-income subsidy (LIS) benefit structure mandated by CMS. The Kaiser Family Foundation estimates that approximately 13 million Medicare beneficiaries receive the LIS, and dual-eligible members enrolled in EmblemHealth D-SNP plans qualify automatically.

Why Insurers Almost Always Cover Metformin Generously

Metformin's favorable formulary placement across nearly every U.S. insurer, including EmblemHealth, reflects three converging factors: clinical evidence, safety profile, and cost.

The clinical case is strong. Metformin has been a first-line therapy for type 2 diabetes since the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated in 1998 that metformin reduced diabetes-related mortality by 42% in overweight patients compared to conventional dietary therapy (P<0.002, N=753). The ADA, the American Association of Clinical Endocrinology (AACE), and the European Association for the Study of Diabetes (EASD) all recommend metformin as initial pharmacotherapy for most adults with type 2 diabetes. The 2024 ADA Standards of Care states: "Metformin should be initiated at the time of type 2 diabetes diagnosis unless contraindicated."

Safety data spans more than 60 years of global clinical use. The most significant safety concern, lactic acidosis, occurs at an estimated rate of 3 to 10 cases per 100,000 patient-years according to a meta-analysis published in the Cochrane Database, and this rate is not significantly higher than in patients taking other diabetes medications. The FDA relaxed its boxed warning regarding metformin use in patients with mild-to-moderate renal impairment in 2016, expanding the eligible patient population.

The cost argument is simple. Generic metformin is among the least expensive prescription medications available. The average cash price for metformin 500 mg #60 (a common 30-day supply at 1,000 mg/day) is $4 to $8 at major retail chains. For an insurer like EmblemHealth that manages hundreds of thousands of diabetic members, covering metformin generously reduces downstream costs from poorly controlled diabetes: hospitalizations, amputations, dialysis, and cardiovascular events that each cost tens of thousands of dollars per episode.

Metformin for Off-Label Uses: Will EmblemHealth Still Cover It?

Metformin is FDA-approved only for type 2 diabetes, but physicians prescribe it off-label for several conditions. The most common off-label uses include polycystic ovary syndrome (PCOS), prediabetes/diabetes prevention, and (increasingly discussed in longevity medicine circles) potential anti-aging effects based on the ongoing TAME trial (Targeting Aging with Metformin).

EmblemHealth's formulary coverage for metformin is not diagnosis-restricted. That means a pharmacy will fill a metformin prescription regardless of whether the prescribing diagnosis is type 2 diabetes, PCOS, or prediabetes. The insurer does not require a specific ICD-10 code to process a Tier 1 generic metformin claim. This is standard practice across major insurers because applying diagnosis-based restrictions to a $4 generic drug would cost more in administrative overhead than it would save.

For PCOS specifically, the Endocrine Society's 2023 clinical practice guideline recommends metformin as an adjunct to lifestyle modification for metabolic features of PCOS, particularly in patients who cannot take or prefer not to take combined oral contraceptives. The Diabetes Prevention Program (DPP) trial (N=3,234) showed that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% over 2.8 years compared to placebo in adults with prediabetes.

As for longevity-focused prescribing, the TAME trial is currently recruiting participants aged 65 to 79 to study whether metformin delays age-related diseases. Results are not yet available, so evidence-based longevity claims remain preliminary. EmblemHealth will still cover the prescription if a licensed prescriber writes it, but the clinical rationale sits on softer ground.

How to Verify Your Specific EmblemHealth Metformin Coverage

Formulary details vary by plan, plan year, and employer group. The general information in this article applies to the majority of EmblemHealth products, but confirming your specific coverage takes only a few minutes.

Check your plan's formulary online by logging into the EmblemHealth member portal and navigating to "Pharmacy Benefits" or "Find a Drug." Enter "metformin" to see the tier, copay, and any utilization management requirements for your exact plan.

Call the number on the back of your EmblemHealth member ID card. The pharmacy benefits team can confirm your copay, tell you which pharmacies are preferred (for the lowest copay), and explain whether mail-order is available on your plan.

Ask your pharmacist to run a test claim. This generates real-time adjudication through EmblemHealth's pharmacy benefit manager and shows your exact out-of-pocket cost before you commit to filling the prescription.

If your copay is higher than expected, ask your prescriber whether a different metformin formulation (switching from brand to generic, or from ER to IR) could lower your cost. "The choice of metformin formulation should balance tolerability and adherence against out-of-pocket burden," according to the ADA's 2024 cost-of-care consensus report.

For members without insurance or with high-deductible plans, GoodRx and similar discount programs frequently price generic metformin below $4 for a 30-day supply, which may be less than your insurance copay. In that scenario, paying cash and not running the claim through EmblemHealth could be the cheapest option.

EmblemHealth vs. Other New York Insurers on Metformin Coverage

EmblemHealth's metformin coverage is consistent with what other major New York-area insurers offer. Aetna, UnitedHealthcare, Cigna, and Healthfirst all place generic metformin on Tier 1 with copays ranging from $0 to $15. The New York State Department of Financial Services requires all qualified health plans sold on the NY State of Health marketplace to cover essential prescription drug benefits, and metformin qualifies under every benchmark formulary.

Where EmblemHealth stands out slightly is in its Essential Plan offerings for lower-income New Yorkers. These plans charge $0 for Tier 1 generics with no deductible, making metformin completely free. Some competing plans charge $1 to $3 for generics on similar essential plan tiers. The difference is small in absolute terms but meaningful for members filling multiple prescriptions monthly.

A 2022 study in Health Affairs found that even small copays ($1 to $5) for diabetes medications were associated with measurably lower adherence rates among low-income populations compared to $0-copay designs. EmblemHealth's zero-dollar generic tier for Essential Plan members aligns with this evidence.